The Management of Uterine Sarcomas

Clinical Oncology

Volumn 20, Issue 6, 2008, Pages 470-478

  Reed, N S ^a  

^a WESTERN INFIRMARY   (United Kingdom)

Author keywords

Carcinosarcomas; chemotherapy; leiomyosarcomas; radiation; uterine

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DACTINOMYCIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; GESTAGEN; GRANULOCYTE COLONY STIMULATING FACTOR; HORMONE; IFOSFAMIDE; MEGESTROL ACETATE; MESNA; METHOTREXATE; MITOMYCIN; PACLITAXEL; PLATINUM DERIVATIVE; TAMOXIFEN; TAXANE DERIVATIVE; TOPOTECAN; TRABECTEDIN; VINCRISTINE;

ABDOMINAL HYSTERECTOMY; ADJUVANT THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER GRADING; CANCER HORMONE THERAPY; CANCER RELAPSE; CANCER STAGING; CARCINOSARCOMA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG DOSE REGIMEN; DRUG MEGADOSE; DRUG TREATMENT FAILURE; ENDOMETRIUM SARCOMA; FEMALE; HUMAN; LEIOMYOSARCOMA; LUNG METASTASIS; LYMPHADENECTOMY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POSTOPERATIVE CARE; PRIORITY JOURNAL; SALPINGOOOPHORECTOMY; UNSPECIFIED SIDE EFFECT; UTERUS SARCOMA;

CARCINOSARCOMA; DISEASE PROGRESSION; FEMALE; HUMANS; LEIOMYOSARCOMA; NEOPLASM RECURRENCE, LOCAL; POSTOPERATIVE PERIOD; SARCOMA, ENDOMETRIAL STROMAL; TIME FACTORS; UTERINE CERVICAL NEOPLASMS;

EID: 46249091104     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2008.04.002     Document Type: Article

References (84)

1. McCluggage W.G. Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas?. J Clin Pathol 55 5 (2002) 460-469
2. Zelmanowicz A., Hildesheim A., Sherman M.E., et al. Evidence for a common aetiology for endometrial carcinomas and malignant mixed mullerian tumours. Gynecol Oncol 69 (1998) 253-257
3. Amant F., and Vergote I. Bifunctional pathway of uterine carcinosarcomas. Hum Pathol 34 3 (2003) 299
4. Amant F., Dreyer L., Makin J., Vergote I., and Lindeque B.G. Uterine sarcomas in South African black women: a clinicopathologic study with ethnic considerations. Eur J Gynecol Oncol 22 3 (2001) 194-200
5. Sreenan J.J., and Hart W. Carcinosarcomas of the female genital tract. A pathologic study of 29 metastatic tumors; further evidence for the dominant role of the epithelial component and the conversion theory of histogenesis. Am J Surg Pathol 5 (1995) 310-313
6. Amant F., Cadron I., Fuso L., et al. Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high risk epithelial endometrial cancer. Gynecol Oncol 98 (2005) 274-280
7. Evans H.L. Endometrial stromal sarcoma and poorly differentiated endometrial sarcoma. Cancer 50 (1982) 2170-2182
8. Norris H.J., and Taylor H.B. Mesenchymal tumors of the uterus. I. A clinical and pathological study of 53 endometrial stromal tumors. Cancer 19 6 (1966) 755-766
9. Oliva E., Clement P.B., and Young R.H. Endometrial stromal tumors: an update on a group of tumors with a protean phenotype. Adv Anat Pathol 7 5 (2000) 257-281
10. Bergman L., Beelen M.L., Gallee M.P., Hollema H., Benraadt J., and van Leeuwen F.E. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of liver and endometrial cancer risk following tamoxifen. Lancet 356 (2000) 881-887
11. Curtis R., Freedman D.M., Sherman M.E., and Fraumeni J.F. Risk of malignant mixed mullerian tumors after tamoxifen therapy for breast cancer. J Natl Cancer Inst 96 1 (2004) 70-72
12. Brooks S.E., Zhan M., and Baquet C. Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999. Gynecol Oncol 93 (2004) 204-208
13. Arrastia C.D., Fruchter R.G., Clark M., et al. Uterine carcinosarcomas: incidence and trends in management and survival. Gynecol Oncol 65 (1997) 158-163
14. Bokhman J.V. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 15 1 (1983) 10-17
15. Major F.J., Blessing J.A., Silverberg S.G., et al. Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer 71 (1993) 1702-1709
16. Chauveinc L., Deniaud E., Plancher C., et al. Uterine sarcomas: the Curie Institute experience. Prognosis factors and adjuvant treatments. Gynecol Oncol 72 2 (1999) 232-237
17. George M., Pejovic M.H., Kramar A., and Gynecologic Cooperating Group of French Oncology Centers. Uterine sarcomas: prognostic factors and treatment modalities-study on 209 patients. Gynecol Oncol 24 (1986) 58-67
18. Gadducci A., Sartori E., Landoni F., et al. The prognostic relevance of histological type in uterine sarcomas: a Cooperation Task Force (CTF) multivariate analysis of 249 cases. Eur J Gynecol Oncol 23 4 (2002) 295-299
19. Amant F. The rationale for comprehensive surgical staging in endometrial carcinosarcoma. Gynecol Oncol 99 2 (2005) 521-522
20. Edwards C.L. Undifferentiated tumours. Cancer of uterus and ovary year book 1969, MD Anderson Hospital and Tumor Institute at Houston (1969), Year Book Medical Publishers, Chicago 84-94
21. Badib A.O., Vongtama V., Kurohara S.S., and Webster J.H. Radiotherapy in the treatment of sarcomas of the corpus uteri. Cancer 24 (1969) 724-729
22. Belgrad R., Elbadawi N., and Rubin P. Uterine sarcoma. Radiology 144 1 (1975) 181-188
23. Salazar O., Bonfiglio T.K., Patten S.F., et al. Uterine sarcomas: natural history, treatment and prognosis. Cancer 42 (1978) 1152-1160
24. Salazar O.M., Bonfiglio T.A., Patten S.F., et al. Uterine sarcomas. Analysis of failures with special emphasis on the use of adjuvant radiotherapy. Cancer 42 (1978) 1161-1170
25. Sorbe B. Radiotherapy and/or chemotherapy as adjuvant treatment of uterine sarcomas. Gynecol Oncol 20 (1985) 281-289
26. Hornback N.B., Omura G., and Major F.J. Observations on the use of adjuvant radiation therapy in patients with stage I and II uterine sarcoma. Int J Radiat Oncol Biol Phys 12 12 (1986) 2127-2130
27. Le T. Adjuvant pelvic radiotherapy for uterine carcinosarcoma in a high risk population. Eur J Surg Oncol 27 3 (2001) 282-285
28. Chi D.S., Mychalczak B., Saigo P.E., Rescigno J., and Brown C.L. The role of whole pelvic irradiation in the treatment of early-stage uterine carcinosarcoma. Gynecol Oncol 65 (1997) 493-498
29. Dusenbery K.E., Potish R.A., Agenta P.A., et al. On the apparent failure of adjuvant pelvic radiotherapy to improve survival for women with uterine sarcomas confined to the uterus. Am J Clin Oncol 28 (2005) 295-300
30. Reed N.S., Mangioni C., Malmstrom H., et al. First results of a randomised trial comparing radiotherapy versus observation postoperatively in patients with uterine sarcomas, an EORTC-GCG study. ESGO Congress. Int J Gynecol Cancer 13 (2003) 4
31. Wolfson A.H., Brady M.F., Rocereto T.F., et al. A Gynecologic Oncology Group randomized trial of whole abdominal irradiation (WAI) vs cisplatin-ifosfamide and mesna (CIM) as post surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecol Oncol 107 2 (2007) 177-185
32. Kitchener HC, Redman CW, Swart AMC, Amos CL. ASTEC (surgery component): a study in the treatment of endometrial cancer: a randomised trial of lymphadenectomy in the treatment of endometrial cancer. 14th International Meeting of the European Society of Gynaecological Oncology Istanbul, 28 September 2005.
33. Chan J.K., Wu H., Cheung M.K., Shin J.Y., Osann K., and Kapp D.S. The outcomes of 27,063 women with unstaged endometrioid uterine cancer. Gynecol Oncol 106 2 (2007) 282-288
34. Kong A., Johnson N., Cornes P., et al. Adjuvant radiotherapy for stage I endometrial cancer. Availabe from:. http://thecochranelibrary.com
35. Kong A., Simera I., Collingwood M., Williams C., Kitchener H.K., and on behalf of Cochrane Gynaecological Cancer Group. Adjuvant radiotherapy for stage I endometrial cancer: systematic review and meta-analysis. Ann Oncol 18 (2007) 1595-1604
36. Creutzberg C.L., van Putten W.L., Koper P.C., et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 355 9213 (2000) 1404-1411
37. Hogberg T., Rosenberg P., Kristensen G., et al. A randomised phase III study on adjuvant treatment with radiation (RT) ± chemotherapy (CT) in early stage high risk endometrial cancer (NSGO 9505/EORTC 55991). Proc ASCO (2007) [abstract 5503]
38. Hoskins P.J., Le N., Ellard S., et al. Carboplatin plus paclitaxel for advanced or recurrent uterine malignant mixed mullerian tumors. The British Columbia Cancer Agency experience. Gynecol Oncol 108 1 (2008) 58-62
39. Leath C.A., Huh W.K., Hyde J., et al. A multi-institutional review of outcomes of endometrial stromal sarcoma. Gynecol Oncol 105 3 (2007) 630-634
40. Fiorica J.V., Brunetto G., Hanjani P., Lentz S.S., Mannel R., and Andersen W. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 92 1 (2004) 10-14
41. Crawford D., George W.D., Smith D.C., Stewart M., Paul J., and Leake R. Cyclic sequential endocrine therapy for advanced breast cancer using a combination of tamoxifen and megestrol acetate. Oncology 51 Suppl 1 (1994) 13-18
42. Gadducci A., Landoni F., Sartori E., et al. Uterine leiomyosarcoma: analysis of treatment failures and survival. Gynecol Oncol 62 (1996) 25-32
43. Giuntoli R.L., Metzinger D.S., DiMarco C.S., et al. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management and adjuvant therapy. Gynecol Oncol 89 (2004) 460-469
44. Omura G.A., Blessing J.A., Major F.J., et al. A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group study. J Clin Oncol 3 (1985) 1240-1245
45. Sutton G.P., Blessing J.A., Rosenshein N., Photopoulos G., and DiSaia P.J. Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (a Gynecologic Oncology Group study). Am J Obstet Gynecol 161 (1989) 309-315
46. Tierney J.F., Mosseri V., Stewart L.A., Souhami R., and Parmar M.K. Adjuvant chemotherapy for soft-tissue sarcoma: review and meta-analysis of the published results of randomised clinical trials. Br J Cancer 72 2 (1995) 469-475
47. Sutton G., Kauderer J., Carson L.F., Lentz S., Whitney C.W., and Gallion H. Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus. A Gynecologic Oncology Group study. Gynecol Oncol 96 (2005) 630-634
48. Pautier P., Rey A., Haie-Meder C., et al. Adjuvant chemotherapy with cisplatin, ifosfamide, and doxorubicin followed by radiotherapy in localised uterine sarcomas: results of a case-controlled study with radiotherapy alone. Int J Gynecol Cancer 14 (2004) 1112-1117
49. Manolitsas T.P., Wain G.V., Williams K., et al. Multimodality therapy for patients with clinical stage I and II malignant mixed mullerian tumors of the uterus. Cancer 91 (2001) 1437-1443
50. Kanjeeka S., Chambers A., Kee Fung M.F., Verma S., on behalf of the Cancer Care Ontario Practice Guidelines Initiative Gynecology, Cancer Disease Site Group Program in Evidence-Based Care, Cancer Care Ontario, and Canada. Systemic therapy for advanced uterine sarcoma: a systematic review of the literature. Gynecol Oncol 97 (2005) 624-637
51. Omura G.A., Major F.J., Blessing J.A., et al. A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. Cancer 52 (1983) 626-632
52. Muss H.B., Bundy B., DiSaia P.J., et al. Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a phase II trial of the Gynecologic Oncology Group). Cancer 55 (1985) 1648-1653
53. Gershenson D.M., Kavanagh J.J., Copeland L.J., Edwards C.L., Freedman R.S., and Wharton J.T. High-dose doxorubicin infusion therapy for disseminated mixed mesodermal sarcoma of the uterus. Cancer 59 (1987) 1264-1267
54. Thigpen J.T., Blessing J.A., Orr J.W., and DiSaia P.J. Phase II trial of cisplatin in the treatment of patients with advanced or recurrent mixed mesodermal sarcoma of the uterus: a Gynecologic Oncology Group study. Cancer Treat Rep 70 (1986) 271-274
55. Gershenson D.M., Kavanagh J.J., Copeland L.J., Edwards C.L., Stringer C.A., and Wharton J.T. Cisplatin therapy for disseminated mixed mesodermal sarcoma of the uterus. J Clin Oncol 5 (1987) 618-621
56. Thigpen J.T., Blessing J.A., Beecham J., Homesley H., and Yordan E. Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas: a Gynecologic Oncology Group study. J Clin Oncol 9 (1991) 1962-1966
57. Sutton G., Blessing J.A., Park R., DiSaia P.J., and Rosenshein N. Ifosfamide treatment of recurrent or metastatic endometrial stromal sarcomas previously unexposed to chemotherapy: a study of the GOG. Obstet Gynecol 87 5 Pt 1 (1996) 747-750
58. Sutton G., Blessing J.A., and Ball H. Phase II trial of paclitaxel in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 74 (1999) 346-349
59. Gallup D.G., Blessing J.A., Andersen W., and Morgan M.A. Evaluation of paclitaxel in previously treated leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 89 (2003) 48-51
60. Miller D.S., Blessing J.A., Kilgore L.C., Mannel R., and Van Le L. Phase II trial of topotecan in patients with advanced, persistent or recurrent uterine leiomyosarcomas: a Gynecologic Oncology Group study. Am J Clin Oncol 23 (2000) 355-357
61. Hannigan E.V., Elder K.W., and Rutledge F.N. Treatment of advanced uterine sarcoma with vincristine, actinomycin D and cyclophosphamide. Gynecol Oncol 15 (1983) 224-229
62. Willemse P.H.B., Bouma J., and Hollema H. Cisplatin in gynecologic carcinosarcoma. J Clin Oncol 10 (1992) 1365 [letter]
63. Baker T., Piver M.S., Caglar H., and Piedmonte M. Prospective trial of cisplatin, adriamycin and dacarbazine in metastatic mixed mesodermal sarcomas of the uterus and ovary. Am J Clin Oncol 14 (1991) 246-250
64. Campos S., Penson R.T., Matulonis U.A., et al. A phase 2 and pharmacokinetic/dynamic study of Doxil and weekly paclitaxel chemotherapy for recurrent Mullerian tumors. Proc Am Soc Clin Oncol 19 (2000) 410a [abstract]
65. Leyvraz S., Bacchi M., Lissoni A., Sessa C., Cerny T., and Honegger H.P. High response rate with the combination of high-dose ifosfamide and doxorubicin for the treatment of advanced gynecologic sarcomas. Proc Am Soc Clin Oncol 17 (1998) 354a [abstract]
66. Leyvraz S., Zweifel M., Jundt G., et al. Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas. Ann Oncol 17 (2006) 646-651
67. Fuller A.F., Penson R.T., Supko J.G., et al. A phase I/II and pharmacokinetic study of 96-hour infusional topotecan and paclitaxel chemotherapy for recurrent mullerian sarcomas. Proc Am Soc Clin Oncol 19 (2000) 392a [abstract]
68. Sutton G., Brunetto V.L., Kilgore L., et al. A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 79 (2000) 147-153
69. van Rijswijk R.E.N., Vermorken J.B., Reed N., et al. Cisplatin, doxorubicin and ifosfamide in carcinosarcoma of the female genital tract. A phase II study of the European Organization for Research and Treatment of Cancer Gynecological Cancer Group (EORTC 55923). Eur J Cancer 39 (2003) 481-487
70. Homesley H., Filiaci G., Markman M., et al. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group study. J Clin Oncol 25 5 (2007) 526-531
71. Sutton G.P., Blessing J.A., and Malfetano J.H. Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 62 (1996) 226-229
72. Edmonson J.H., Blessing J.A., Cosin J.A., Miller D.S., Cohn D.E., and Rotmensch J. Phase II study of mitomycin, doxorubicin, and cisplatin in the treatment of advanced uterine leiomyosarcoma: a Gynecologic Oncology Group study. Gynecol Oncol 85 3 (2002) 507-510
73. Hensley M.L., Maki R., Venkatraman E., et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 12 (2002) 2824-2831
74. Yamawaki T., Shimzu Y., and Hasumi K. Treatment of stage IV "high-grade" endometrial stromal sarcoma with ifosfamide, adriamycin and cisplatin. Gynecol Oncol 64 2 (1997) 265
75. Curtin J.P., Blessing J.A., Soper J.T., and DeGeest K. Paclitaxel in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 83 (2001) 268-270
76. Duska L.R., Garrett A., Eltabbakh G.H., Oliva E., Penson R., and Fuller A.F. Paclitaxel and platinum chemotherapy for malignant mullerian tumors of the ovary. Gynecol Oncol 85 (2002) 459-463
77. Szlosarek P.W., Lofts F.J., Pettengell R., Carter P., Young M., and Harmer C. Effective treatment of a patient with a high-grade endometrial stromal sarcoma with an accelerated regimen of carboplatin and paclitaxel. Anti-cancer Drugs 11 4 (2000) 275-278
78. Sutton G.P., Blessing J.A., Barrett R.J., and McGehee R. Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Am J Obstet Gynecol 166 (1992) 556-559
79. Schoffski P., Wolter P., Clement P., et al. Trabectedin (ET-743): evaluation of its use in advanced soft-tissue sarcoma. Future Oncol 3 4 (2007) 381-392
80. Lorigan P., Verweij J., Papai Z., et al. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 25 21 (2007) 3144-3150
81. Levenback C., Rubin S.C., McCormack P.M., et al. Resection of pulmonary metastases from uterine sarcomas. Gynecol Oncol 45 (1992) 202-205
82. Leitao M.M., Brennan M.F., Hensley M., et al. Surgical resection of pulmonary and extrapulmonary recurrences of uterine leiomyosarcoma. Gynecol Oncol 87 (2002) 287-294
83. Mountain C.F., McMurtrey M.J., and Hermes K.E. Surgery for pulmonary metastasis: a 20-year experience. Ann Thorac Surg 38 (1984) 323-330
84. Reed N.S., Mangioni C., Malmstrom H., et al. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer 44 6 (2008) 808-818